Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Berliere M et al. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen. Eur J Cancer 2004;40(12):1855-61. Abstract

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;Abstract 3.

Boccardo F et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 2001;19(22):4209-15. Abstract

Buzdar AU; ATAC trialists’ group. ‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer — efficacy overview. J Steroid Biochem Mol Biol 2003;86(3-5):399-403. Abstract

Castiglione-Gertsch M et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003;95(24):1833-46. Abstract

Coleman R et al. Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial. Proc ASCO 2004;Abstract 767.

Colleoni M et al. Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with nodepositive (N+), early stage breast cancer: First results of International Breast Cancer Study Group Trial 13-93. Proc ASCO 2004;Abstract 532.

Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Coombes RC et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifenupdated survival analysis. Breast Cancer Res Treat 2004;Abstract 3.

Curigliano G et al. Adjuvant therapy for very young women with breast cancer: Response according to biologic and endocrine features. Clin Breast Cancer 2004;5(2):125-30. Abstract

de Haes H et al; Zoladex Early Breast Cancer Research Association Trialists Group. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with nodepositive, early breast cancer: The Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol 2003;21(24):4510-6. Abstract

Distler W et al. Impact of age on the gynecologic adverse event (AE) profile of anastrozole (A) or tamoxifen (T) in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2004;Abstract 770.

Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;83(Suppl 1):7;Abstract 4.

Duffy S et al. The ATAC adjuvant breast cancer trial in postmenopausal women: Baseline endometrial subprotocol data. BJOG 2003;110(12):1099-106. Abstract

Emens LA, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 2003;9(1 Pt 2):486S-94S. Abstract

Fallowfield LJ et al. Intergroup exemestane study: Results of the quality of life sub-protocol. Breast Cancer Res Treat 2004;Abstract 4.

Fogelman I et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14(12):1001-6. Abstract

Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res Treat 2004;Abstract 6.

Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. Breast Cancer Res Treat 2002;Abstract 12.

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Howell A et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer — updated efficacy results based on a median follow-up of 5 years. Breast Cancer Res Treat 2004;Abstract 1.

Jakesz R et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;Abstract 2.

Jakesz R et al; Austrian Breast and Colorectal Cancer Study Group Trial 5. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer — Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20(24):4621-7. Abstract

Jonat W et al; Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20(24):4628-35. Abstract

Kaufmann M et al; Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists’ Group. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003;39(12):1711-7. Abstract

Locker GY et al. The time course of bone fractures observed in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003;Abstract 98.

Love RR et al. Duration of signs and survival in premenopausal women with breast cancer. Breast Cancer Res Treat 2004;86(2):117-24. Abstract

Love RR et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003;21(3):453-7. Abstract

Love RR et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20(10):2559-66. Abstract

Love RR, Niederhuber JE. Models of breast cancer growth and investigations of adjuvant surgical oophorectomy. Ann Surg Oncol 2004;11(9):818-28. Abstract

Robertson JF, Blamey RW. The use of gonadotrophin- releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 2003;39(7):861- 9. Abstract

Sainsbury R. Ovarian ablation as a treatment for breast cancer. Surg Oncol 2003;12(4):241-50. Abstract

Slanetz PJ et al. Effect of tamoxifen on breast tissue density in premenopausal breast cancer. Breast J 2004;10(1):27-32. Abstract

Sverrisdottir A et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004;22(18):3694-9. Abstract

Thomson CS et al; Scottish Cancer Trials Breast Group; Scottish Cancer Therapy Network. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 2002;11(5):419- 29. Abstract